Navigation Links
'Cornell Dots' that light up cancer cells go into clinical trials
Date:1/31/2011

ITHACA, N.Y. - "Cornell Dots" brightly glowing nanoparticles may soon be used to light up cancer cells to aid in diagnosing and treating cancer. The U.S. Food and Drug Administration (FDA) has approved the first clinical trial in humans of the new technology. It is the first time the FDA has approved using an inorganic material in the same fashion as a drug in humans.

"The FDA approval finally puts a federal approval stamp on all the assumptions we have been working under for years. This is really, really nice," said Ulrich Wiesner, the Spencer T. Olin Professor of Materials Science and Engineering, who has devoted eight years of research to developing the nanoparticles. "Cancer is a terrible disease, and my family has a long history of it. I, thus, have a particular personal motivation to work in this area."

The trial with five melanoma patients at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York City will seek to verify that the dots, also known as C dots, are safe and effective in humans, and to provide data to guide future applications. "This is the first product of its kind. We want to make sure it does what we expect it to do," said Michelle Bradbury, M.D., radiologist at MSKCC and assistant professor of radiology at Weill Cornell Medical College.

C dots are silica spheres less than 8 nanometers in diameter that enclose several dye molecules. (A nanometer is one-billionth of a meter, about the length of three atoms in a row.) The silica shell, essentially glass, is chemically inert and small enough to pass through the body and out in the urine. For clinical applications, the dots are coated with polyethylene glycol so the body will not recognize them as foreign substances.

To make the dots stick to tumor cells, organic molecules that bind to tumor surfaces or even specific locations within tumors can be attached to the shell. When exposed to near-infrared light, the dots fluoresce much brighter than unenca
'/>"/>

Contact: Blaine Friedlander
bpf2@cornell.edu
607-254-8093
Cornell University
Source:Eurekalert

Page: 1 2

Related biology news :

1. Gates Foundation continues funding of tuberculosis research at Weill Cornell
2. Cornells regional sun grant energy conference is May 24-26
3. Cornell forges licensing agreement with new New York apple industry group
4. Weill Cornell researchers find that a single gene is responsible for OCD-like behaviors in mice
5. Weill Cornell science briefs: November 2009
6. Battling cancer with engineering: NCI funds new $13 million cancer research center led by Cornell
7. Genetic secrets of date palm unlocked by researchers at Weill Cornell Medical College in Qatar
8. NIST-Cornell team builds worlds first nanofluidic device with complex 3-D surfaces
9. Multicolor quantum dots aid in cancer biopsy diagnosis
10. Connecting the dots: How light receptors get their message across
11. Rice eyes risks of quantum dots
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... The genome of Solanum pennellii , a wild ... an international group of researchers including the labs headed ... UC Davis Department of Plant Biology. The new genome ... , The work, published July 27 in the journal ... and colleagues at Aachen University in Germany. The UC ...
(Date:7/28/2014)... calls himself the bug hunter, but the target of ... found and identified with special methods and instruments. Benjamin ... Veterinary Diagnostic Laboratory at Kansas State University, recently published ... G, which is an important find in the United ... but didn,t know what it was," Hause said. "We ...
(Date:7/28/2014)... DUBLIN , July 28, 2014 ... the "Biometrics Market in Latin America 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Biometrics measure and analyze biological ... facial patterns, irises, eye retinas, voice patterns, and hand ... one or more stored templates. The main purpose of ...
Breaking Biology News(10 mins):Researcher using next-generation sequencing to rapidly identify pathogens 2Researcher using next-generation sequencing to rapidly identify pathogens 3Biometrics Market in Latin America 2014-2018 2
... DURHAM, N.H. University of New Hampshire ... $498,115 to advance understanding of the actinorhizal plants, ... and contaminated soils. The United States ... of molecular, cellular and biomedical sciences, $399,000 to ...
... toads have existed for 360 million years and survived when ... to make many of them extinct, according to an article ... The fungus, Batrachochytrium dendrobatidis (Bd), was found ... America and north-eastern Australia in the 1990,s. Bd infects over ...
... for Child Health Research has found evidence that the amount ... in different ways. The study has just been published ... author Colleen O,Leary said the analysis was drawn from a ... questionnaire three months after the baby,s delivery, and were then ...
Cached Biology News:UNH prof. receives nearly $500,000 to research environmentally significant plants 2New study links alcohol in pregnancy to child behavior problems 2
(Date:7/29/2014)... 29, 2014 ... zur Erfassung biologischer Daten in Verbindung mit ... patentiert. Das LBS nimmt gleichzeitig mehrere Blutproben ... Patienten und sucht erhöhte biologische Aktivitäten in ... die Entdeckung und Entwicklung neuer Medikamente und ...
(Date:7/28/2014)... The Workgroup for Electronic Data Interchange (WEDI), the ... IT to create efficiencies in healthcare information exchange, announced ... has developed an issue brief titled, “What is the ... Workgroup, a part of WEDI’s Strategic National HPID Implementation ... Medicaid Services (CMS) to identify common misuse of the ...
(Date:7/28/2014)... CA and Annapolis Junction, MD (PRWEB) July 28, 2014 ... and research leader in personalized medicine, will be exhibiting ... services at this year’s International Spine Intervention Society’s ... take place July 30th-August 3rd, at the Hyatt Regency, ... designed to enhance the knowledge and clinical competence of ...
(Date:7/28/2014)... July 28, 2014 ... Identification Market by Products (Consumables, Instruments, Services), Methods (Phenotypic, ... User (Detection, Characterization) - Global Forecasts to ... Market is estimated at $896.5 Million in ... Million by 2019, growing at a CAGR ...
Breaking Biology Technology:PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 2PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 3PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 4WEDI’s HPID Workgroup Announces Release of Issue Brief: “What is the Difference Between a Health Plan and Payer?” 2Proove Biosciences Exhibits Industry Leading Data and Research at International Spine Intervention Society’s 22nd Annual Scientific Meeting 2Microbial Identification Market worth $1,194.1 Million by 2019 2Microbial Identification Market worth $1,194.1 Million by 2019 3
... Savient,Pharmaceuticals, Inc. (Nasdaq: SVNT ) today announced ... Pharmaceuticals,will present a corporate update at the upcoming Lazard ... scheduled to begin on Tuesday, November 18, 2008 at,9:25 ... St. Regis Hotel in New,York City November 18-19, 2008., ...
... PharmAthene, Inc.,(NYSE Alternext US: PIP), a biodefense ... today reported,financial and operational results for the third ... For the third quarter of 2008, PharmAthene recognized ... the same period of 2007. For the nine,months ...
... Stops Bleeding Wins Professor Venture Fair at,U-Md. Bioscience Day, ... of,Maryland professor and doctoral student team who invented a ... a group of venture,capitalists and the title of "Best ... Sponsored by the university,s Office of Technology Commercialization,the ...
Cached Biology Technology:Savient Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference on November 18th 2Pharmathene Reports Third Quarter 2008 Financial and Operational Results 2Pharmathene Reports Third Quarter 2008 Financial and Operational Results 3Pharmathene Reports Third Quarter 2008 Financial and Operational Results 4Pharmathene Reports Third Quarter 2008 Financial and Operational Results 5Pharmathene Reports Third Quarter 2008 Financial and Operational Results 6Pharmathene Reports Third Quarter 2008 Financial and Operational Results 7Nano-Velcro Sticks With Venture Capitalists 2Nano-Velcro Sticks With Venture Capitalists 3